Seer Bio
IPOUnbiased, deep, rapid proteomics at scale
- Headquarters
- Redwood City
- Employees
- 51–200
- Founded
- 2017
- Business Model
- B2B
- Website
- seer.bio
- Total Funding
- $111.0M
- Last Round
- $55.0M Series DJul 2020
- Rounds
- 4
- Type
- Public
About
Seer is a life sciences company commercializing the Proteograph Product Suite, a disruptive platform for large-scale, unbiased proteomics. Its nanoparticle-based technology enables researchers to access the breadth and depth of the proteome from plasma samples, advancing cancer, cardiovascular, and neurodegenerative disease research. Seer is publicly traded on Nasdaq (SEER) and headquartered in Redwood City, California.
Tech & App Stack
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingSign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Create Free AccountFunding History
Dec 2020
Sign up to see all 5 rounds
Full funding history, per-round amounts, and investor participation.
Create Free AccountInvestors
Sign up to view investors
Create a free account to see which investors have funded this company.
Create Free AccountSimilar Companies
Global contract development and manufacturing organization (CDMO) focused exclusively on sterile ...
AI-first drug discovery company using AlphaFold-derived models to design therapeutics and acceler...
Biopharmaceutical services company
Specialty pharmaceutical company
Food technology company creating plant-based meat and dairy products that replicate the taste and...
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.